Use and Effectiveness of Continuous Subcutaneous Insulin Infusion (CSII) and Multiple Daily Insulin Injection Therapy (MIT) in Children, Adolescents and Young Adults with Type 1 Diabetes Mellitus

 

 Buy Article Permissions and Reprints

Abstract

Today continuous subcutaneous insulin infusion (CSII) is frequently used in children and adolescents with type 1 diabetes mellitus. The present cross-sectional trial aimed to document current practice, quality of diabetes control and incidence of acute complications in different age-groups under CSII vs. multiple daily insulin injection therapy (MIT). Moreover the survey analyzed socio-demographic backgrounds of the patients.

Patients and methods: A total of 901 patients (age 11.5±4.0, diabetes duration 4.0±3.6 years) was entered in the database. Clinical data, laboratory parameters and, using a standardized questionnaire, socio-demographic data were assessed. For age-related analyses patients were allocated to 4 groups: pre-school children (< 6 years), pre-adolescents (≥ 6 and<11 years), adolescents (≥ 11 and<16 years) and young adults (≥ 16 and<22 years).

Results: Of the cohort n=194 had a CSII, n=707 had a MIT. Patients with CSII vs. MIT had a longer diabetes duration, they used more frequently insulin analogues, performed more frequently blood-glucose self-tests and had a lower insulin dosage per kilogram body weight. In respect of HbA1c, the mean amplitude of blood-glucose excursions, but also of lipids, creatinine, microalbuminuria and blood pressure, there were no differences in neither age-group between patients with CSII and MIT. In patients with CSII and MIT, there was a tendency (p<0.05) towards an increase in HbA1c in adolescents and young adults and there was a decrease (p<0.05 for tendency) in the frequency of hypoglycaemia from the age group of young adults to pre-school children. Adolescents and young adults with CSII had a higher educational level. Pre-adolescents, adolescents and young adults with CSII have also better diabetes-related knowledge. Moreover, in all age-groups, the parents of patients with CSII had mostly a lower unemployment rate and higher educational levels.

Conclusions: The present analyses demonstrate that in all age-groups CSII provides convenient and flexible insulin delivery during routine treatment of type 1 diabetes. There is reasonable quality of diabetes control accompanied by a low incidence of hypoglycaemia and ketoacidosis. However, under CSII and MIT there is an increase of HbA1c towards adolescence. It must also highlighted that CSII seems to be expansive and that CSII is more frequently used in patients with better educational levels and deriving from higher social classes.

• References

• 1 Fuld K, Conrad B, Buckingham B et al. Insulin pumps in young children. Diabetes Technol Ther 2010; 12: S67-S71
  PubMedGoogle Scholar
• 2 Kapellen TM, Klinkert C, Heidtmann B et al. Insulin pump treatment in children and adolescents with type 1 diabetes: Experiences of the German working group for insulin treatment in pediatric patients. Postgrad Med 2010; 122: 98-105
  PubMedGoogle Scholar
• 3 Olsen B, Johannesen J, Fredheim S et al, the Danish society for childhood and adolescent diabetes . Insulin pump treatment: Increasing prevalence, and predictors for better metabolic outcome in Danish children and adolescents with type 1 diabetes. Pediatr Diabetes 2014; DOI: 10.1111/pedi.12164. 25.11.2014
  PubMedGoogle Scholar
• 4 Tamborlane WV, Sikes KA. Insulin therapy in children and adolescents. Endocrinol Metab Clin North Am 2012; 41: 145-160
  CrossrefPubMedGoogle Scholar
• 5 Brancator D, Fleres M, Aiello V et al. The effectiveness and durability of an early insulin pump therapy in children and adolescents with type 1 diabetes mellitus. Diabetes Technol Ther 2014; 16: 735-741
  CrossrefPubMedGoogle Scholar
• 6 Brorsson AL, Viklund G, Ortqvist E et al. Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case-control study. Pediatr Diabetes 2014; DOI: 10.1111/pedi.12209. 19.11.2014
  PubMedGoogle Scholar
• 7 Gong CX, Wei LY, Wu D et al. Effectiveness of multiple daily injections or continuous subcutaneous insulin infusion for children with type 1 diabetes mellitus in clinical practice. Int J Endocrinol 2014; http://dx.doi.org/10.1155/2014/526591 19.11.2014
  PubMedGoogle Scholar
• 8 Mortensen HB, Robertson KJ, Aanstoot HJ et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidore Study Group on Childhood Diabetes. Diabet Med 1998; 15: 752-759
  CrossrefPubMedGoogle Scholar
• 9 Holl RW, Swift PG, Mortensen HB et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: Results from the Hvidore study group. Eur J Pediatr 2003; 162: 22-29
  CrossrefPubMedGoogle Scholar
• 10 Danne T, Battelino T, Jaroz-Chobot P et al. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: Experience of the PedPump Study in 17 countries. Diabetologia 2008; 51: 1594-1601
  CrossrefPubMedGoogle Scholar
• 11 American Diabetes Association . The Expert Committee on the Diagnosis and Classification of Diabetes mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes mellitus. Diabetes Care 1997; 20: 1183-1197
  CrossrefPubMedGoogle Scholar
• 12 Holterhus PM, Beyer P, Bürger Büsing J et al. Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. In: Haak T, Kellerer M. Evidenzbasierte Leitlinien der Deutschen Diabetes-Gesellschaft (DDG). http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/EBL_Kindesalter_2010.pdf 26.03.2013
  Google Scholar
• 13 Arbeitsgemeinschaft Adipositas im Kindes- und Jugendalter (AGA) Leitlinien. Verabschiedet auf der Konsensus-Konferenz der AGA am 10.09.04. http://www.a-g-a.de 04.04.2013
  PubMed
• 14 Guidelines Subcommittee . 1999 World Health Organization – International society of hypertension guidelines for the management of hypertension . J Hyperten 1999; 17: 151-183
  PubMedGoogle Scholar
• 15 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
  CrossrefPubMedGoogle Scholar
• 16 Hasslacher C, Wolf G, Kempe P et al. Diabetische Nephropathie. Diabetologie 2012; 7: S99-S102
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Bortz J. Statistik für Sozialwissenschaftler. 6. Edition Berlin, Germany: Springer Verlag; 2005
  Google Scholar
• 18 Sulmont V, Souchon PF, Gouillard-Darnaud C et al. Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: Continuous subcutaneous insulin infusion as first line treatment. J Pediatr 2010; 157: 103-107
  CrossrefPubMedGoogle Scholar
• 19 Schreiver C, Jacoby U, Watzer B et al. Glycaemic variability in paediatric patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI): A cross-sectional cohort study. Clin Endocrinol (Oxf) 2013; 79: 641-647
  PubMedGoogle Scholar
• 20 Blackmann SM, Raghinaru D, Adi S et al. Insulin pump use in young children in the T1D exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr Diabetes 2014; 15: 564-572
  CrossrefPubMedGoogle Scholar
• 21 Alsaleh FM, Smith FJ, Thompson R et al. Insulin pump therapy: Impact on the lives of children/young people with diabetes mellitus and their parents. Int J. Clin Pharm 2014; 36: 1023-1030
  PubMedGoogle Scholar
• 22 Silverstein J, Klingensmith G, Copeland K. Care of children and adolescents with type 1 diabetes. A statement of the American Diabetes Association. Diabetes Care 2005; 28: 186-212
  CrossrefPubMedGoogle Scholar
• 23 Burdick J, Chase HP, Slover RH et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004; 113: e221-e224
  CrossrefPubMedGoogle Scholar
• 24 Cummins E, Royle P, Snaith A et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: Systematic review and economic evaluation. Health Technol Assess 2010; 14 iii-iv, xi-xvi 1-181 DOI: 10.3310/hta14110.
  PubMedGoogle Scholar
• 25 Petkova E, Petkova V, Konstantinova M et al. Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes – a pilot study: CSII application for children – economic evaluation. BMC Pediatr 2013; 13: 155 DOI: 10.1186/1471-2431-13-155.
  CrossrefPubMedGoogle Scholar
• 26 Roze S, Smith-Palmer J, Valentine W et al. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in type 1 diabetes: A systematic review. Diabet Med 2015; DOI: 10.1111/dme.12792.
  PubMedGoogle Scholar
• 27 Schiel R, Stachow R, Fröhlich C et al. Psychosoziale Charakteristika von Kindern und Jugendlichen mit Typ-1-Diabetes mellitus, die zur stationären Rehabilitation eingewiesen wurden. Eine bundesweite „DPV-Wiss“-Analyse. Diabetologie 2010; 5: 104-109
  Article in Thieme ConnectPubMedGoogle Scholar
• 28 Saboo BD, Talaviya PA. Continuous subcutaneous insulin infusion: Practical issues. Indian J Endocrinol Metab 2012; 16: S259-S262
  PubMedGoogle Scholar
• 29 Health Quality Ontario . Continuous subcutaneous insulin infusion (CSII) pumps for type 1 and type 2 adult diabetic populations: An evidence-based analysis. Ont Health Technol Assess Ser 2009; 9: 1-58
  PubMedGoogle Scholar